BMJ3d
POS0266 CYCLING VS SWAP TNFi AND IL17i IN PSORIATIC ARTHRITIS: RESULTS FROM THE BIRRA RETROSPECTIVE OBSERVATIONAL STUDY
26 University of Modena and Reggio Emilia, Rheumatology Unit, Modena, Italy 27 University of Modena and Reggio Emilia, Rheumatology Unit, Modena, Italy 28 University Hospital of Parma, Internal ...
BMJ3d
Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren’s syndrome shared megakaryocyte expansion in peripheral blood
Objectives Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) share many clinical manifestations and serological features. The aim of this study was to ...
BMJ3d
Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)
1 Center of Clinical Epidemiology, Hôpital Hotel Dieu; INSERM U738, Université Paris-René Descartes, Paris, France Objectives To validate the two recently developed disease activity indexes for ...
BMJ3d
Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein
2 Department of Orthopaedic Surgery (RKU), University of Ulm, Germany 3 Department of Internal Medicine II—Cardiology, University of Ulm, Germany Correspondence to: Dr T Stürmer Department of ...
BMJ3d
Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study
Objective To evaluate the effectiveness and safety of secukinumab in patients with a mucosal and articular Behçet’s phenotype resistant to conventional and biologic treatment. Methods A multicentre ...
BMJ4d
OP0023 GENERATION OF PT101, A HIGHLY SELECTIVE IL-2 MUTEIN FOR TREATMENT OF AUTOIMMUNE DISEASES
4 Pandion Therapeutics, Translational Sciences, Watertown, United States of America 5 Pandion Therapeutics, R&D, Watertown, United States of America Background: Regulatory T cells (Tregs) play a ...
BMJ4d
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
1 Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands Objectives Millions of patients worldwide are treated with therapeutic ...
BMJ4d
2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome
Objectives To develop and validate an international set of classification criteria for primary Sjögren's syndrome (SS) using guidelines from the American College of Rheumatology (ACR) and the European ...
BMJ4d
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...
BMJ4d
Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries
Objectives: To describe the impact of musculoskeletal pain (MP); to compare management of MP by the population and by primary care physicians; and to identify misconceptions about treatment. Methods: ...
BMJ4d
Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2
Correspondence to Professor Daozhang Cai and Dr Xiaochun Bai, Department of Orthopedics, Academy of Orthopedics - Guangdong Province, Orthopedic Hospital of Guangdong Province, The Third Affiliated ...
BMJ4d
Cytokine levels in human synovial fluid during the different stages of acute gout: role of transforming growth factor β1 in the resolution phase
Methods SFs from 38 gouty patients were analysed for white blood cell (WBC) count, percentage of polymorphonuclear cells (PMNs) and levels of interleukin 1β (IL-1β), IL-6, IL-8, tumour necrosis ...